Frequency of K-ras mutation in biliary and pancreatic tumors;Mutación del gen K-ras en tumores pancreático-biliares

Revista Medica de Chile

Volumn 133, Issue 12, 2005, Pages 1434-1440

  Juan Carlos Roa, S ^a   Leonardo Anabalon R ^a   Oscar Tapia, E ^a   Angelica Melo A ^a   De Xabier Aretxabala, U ^b   Ivan Roa E ^a,b  

^a UNIVERSIDAD DE LA FRONTERA   (Chile)

^b UNIVERSIDAD DEL DESARROLLO   (Chile)

Author keywords

Biliary tract neoplasms; Gallbladder neoplasms; Genes, ras; Pancreatic neoplasms

Indexed keywords

ADULT; AGED; ARTICLE; CARCINOMA; CODON; COMPARATIVE STUDY; FEMALE; GALLBLADDER TUMOR; GENETICS; HUMAN; MALE; MIDDLE AGED; MORTALITY; MUTATION; ONCOGENE RAS; PANCREAS TUMOR; PATHOLOGY; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SEX DIFFERENCE; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; CODON; FEMALE; GALLBLADDER NEOPLASMS; GENES, RAS; HUMANS; MALE; MIDDLE AGED; MUTATION; PANCREATIC NEOPLASMS; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; SEX FACTORS; SURVIVAL ANALYSIS;

EID: 32244433615     PISSN: 00349887     EISSN: 07176163     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. ROA I, ARAYA JC, DE ARETXABALA X, SALINAS C, WISTUBA I. Patología de la vesícula biliar en Temuco, IX región. Rev Méd Chile 1989; 117: 889-94.
2. WISTUBA II, ALBORES-SAAVEDRA J. Genetic abnormalities involved in the pathogenesis of gallbladder carcinoma. J Hepatobiliary Pancrea t Surg 1999; 6: 237-44.
3. WISTUBA II, MIQUEL JF, GAZDAR AF, ALBORES-SAAVEDRA J. Gallbladder adenomas have molecular abnormalities different from those present in gallbladder carcinomas. Hum Pathol 1999; 30: 21-5.
4. RASHID A Cellular and molecular biology of biliary tract cancers. Surg Oncol Clin N Am 2002; 11: 995-1009.
5. ROA JC, ROA I, DE ARETXABALA X, MELD A, FARÍA G, TAPIA O. Mutación del gen K-ras en el cáncer de la vesícula biliar. Rev Méd Chile 2004; 132: 955-60.
6. WTSTUBA II, SUGIO K, HUNG J, KISHIMOTO Y, VIRMANI AK, ROA I ET AL Allele-specific mutations involved in the pathogenesis of endemic gallbladder carcinoma in Chile. Cancer Res 1995; 55: 2511-5.
7. WALSH AB, BAR-SAGI D. Differential activation of the Rac pathway by Ha-Ras and K-Ras. J Biol Chem 2001; 276: 15609-15. Epub 2001 Feb 14.
8. MU DQ, PENG YS, XU QJ. Values of mutations of K-ras oncogene at codon 12 in detection of pancreatic cancer: 15 years experience. World J Gastroenterol 2004; 10: 471-5.
9. REN YX, XU GM, LI, ZS, SONG YG. Detection of point mutation in K-ras oncogene at codon 12 in pancreatic diseases. World J Gastroenterol 2004; 10: 881-4.
10. YOSHIDA T, OHNAML S, AOKI K. Development of gene therapy to target pancreatic cancer. Cancer Sci 2004; 95: 283-9.
11. CERNY WL, MANGOLD KA, SCARPELLI DG. K-ras mutation is an early event in pancreatic duct carcinogenesis in the Syrian golden hamster. Cancer Res 1992; 52: 4507-13.
12. VOGEISTEIN KKB. Colorectal tumors. In: Bert V, editor. The genetic basis of human cancer. Second ed. New York: Mac Graw Hill; 2002; 583-612.
13. CLEMENTS NC JR, NELSON MA, WYMER JA, SAVAGE C, AGUIRRE M GAREWAL H. Analysis of K-ras gene mutations in malignant and nonmalignant endobronchial tissue obtained by fiberoptic bronchoscopy. Am J Respir Crit Care Med 1995; 152: 1374-8.
14. ESAPA CT, JOHNSON SJ, KENDALL-TAYLOR P, LENNARD TW, HARRIS PE. Prevalence of Ras mutations in thyroid neoplasia. Clin Endocrinol (Oxf) 1999; 50: 529-35.
15. SAKORAFAS GH, TSIOTOU AG, TSTOTOS GG. Molecular biology of pancreatic cancer; oncogenes, tumour suppressor genes, growth factors, and their receptors from a clinical perspective. Cancer Treat Rev 2000; 26: 29-52.
16. MATSUBAYASHI H, WATANABE H, YAMAGUCHI T, AJIOKA Y, NISMKURA K, KLJIMA H ET AL, Differences in mucus and K-ras mutation in relation to phenotypes of tumors of the papilla of Vater. Cancer 1999; 86: 596-607.
17. ZHAO B, KTMURA W, FUTAKAWA N, MUTO T, KUBOTA K, HARIHARA Y ET AL. p53 and p21/Wafl protein expression and K-ras codon 12 mutation in carcinoma of the papilla of Vater. Am J Gastroenterol 1999; 94: 2128-34.
18. MOTOJIMA K, TSUNODA T, KANEMATSU T, NAGATA Y, URANO T, SHIKU H. Distinguishing pancreatic carcinoma from other periampullary carcinomas by analysis of mutations in the Kirsten-ras oncogene. Ann Surg 1991; 214: 657-62.
19. SCARPA A, CAPELLI P, ZAMBONI G, ODA T, MUKAI K, BONETTI F ET AL Neoplasia of the ampulla of Vater. Ki-ras and p53 mutations. Am J Pathol 1993; 142: 1163-72.
20. MALAIS N, PORTA M, COROMINAS JM, PINOL JL, RIPA J, REAL FX. Ki-ras mutations in exocrine pancreatic cancer: association with clinico-pathological characteristics and with tobacco and alcohol consumption. PANK-ras I Project Investigators. Int J Cancer 1997; 70: 661-7.
21. CHUNG CH, WILENTZ RE, POLAK MM; RAMSOEKH TB, NOORDUYN LA, GOUMA DJ ET AL Clinical significance of K-ras oncogene activation in ampullary neoplasms. J Clin Pathol 1996; 49: 460-4.
22. HOWE JR, KLTMSTRA DS, CORDON-CARDO C, PATY PB, PARK PY, BRENNAN MF. K-ras mutation in adenomas and carcinomas of the ampulla of vater. Clin Cancer Res 1997; 3: 129-33.
23. TADA M, YOKOSUKA O, OMATA M, OHIO M ISONO K. Analysis of ras gene mutations in biliary and pancreatic tumors by polymerase chain reaction and direct sequencing. Cancer 1990; 66: 930-5.
24. LEVI S, URBAND-ISPIZUA A, GILL R, THOMAS DM, GILBERTSON J, FOSTER C ET AL Multiple K-ras codon 12 mutations in cholangiocarcinomas demonstrated with a sensitive polymerase chain reaction technique. Cancer Res 1991; 51: 3497-502.
25. IMAI M, HOSHI T, OGAWA K. K-ras codon 12 mutations in biliary tract tumors detected by polymerase chain reaction denaturing gradient gel electrophoresis. Cancer 1994; 73: 2727-33.
26. RIJKEN AM, VAN GULIK TM, POLAK MM STURM PD, GOUMA DJ, OFFERHAUS GJ. Diagnostic and prognostic value of incidence of K-ras codon 12 mutations in resected distal bile duct carcinoma. J Surg Oncol 1998; 68: 187-92.
27. SUTO T, HABANO W, SUGAL T, UESUGI N, FUNATO O, KANNO S ET AL Aberrations of the K-ras, p53, and APC genes in extrahepatic bile duct cancer. J Surg Oncol 2000; 73: 158-63.
28. ZHOU M, HUANG SG, WAN HY, LI B, DENG WW, LI M Genetic polymorphism in matrix metallopro teinase-9 and the susceptibility to chronic obstructive pulmonary disease in Han population of south China. Chin Med J (Engl) 2004; 117: 1481-4.
29. UEMURA T, HIBI K, KANEKO T, TAKEDA S, INDUE S, OKOCHI O ET AL Detection of K-ras mutations in the plasma DNA of pancreatic cancer patients. J Gastroenterol 2004; 39: 56-60.
30. RASHID A, UEKI T, GAO YT, HOULIHAN PS, WALLACE C, WANG BS ET AL K-ras mutation, p53 overexpression, and microsatellite instability in biliary tract cancers: a population-based study in China. Clin Cancer Res 2002; 8: 3156-63.
31. HANADA K, ITOH M FUJII K, TSUCHIDA A, OOISHI H, KAJIYAMA G. K-ras and p53 mutations in stage I gallbladder carcinoma with an anomalous junction of the pancreaticobiliary duct. Cancer 1996; 77: 452-8.
32. HLDAKA E, YANAGISAWA A, SEKL M, TAKANO K, SETOGUCHI T, KATO Y. High frequency of K-ras mutations in biliary duct carcinomas of cases with a long common channel in the papilla of Vater. Cancer Res 2000; 60: 522-4.
33. KIM SW, HER KH, JANG JY, KM WH, KM YT, PARK YH. K-ras oncogene mutation in cancer and precancerous lesions of the gallbladder. J Surg Oncol 2000; 75: 246-51.
34. AJIKI T, FUJIMORI T, ONOYAMA H, YAMAMOTO M, KITAZAWA S, MAEDA S ET AL K-ras gene mutation in gallbladder carcinomas and dysplasia. Gut 1996; 38: 426-9.
35. AHRENDT SA, RASHID A, CHOW JT, ETSENBERGER CF, PITT HA, STDRANSKY D. p53 overexpression and K-ras gene mutations in primary sclerosing cholangitis-associated biliary tract cancer. J Hepa tobiliary Pancreat Surg 2000; 7: 426-31.
36. WATANABE H, HA A, HU YX, OHTSUBO K, YAMAGUCHI Y, MJTOO Y ET AL K-ras mutations in duodenal aspirate without secretin stimulation for screening of pancreatic and biliary tract carcinoma. Cancer 1999; 86: 1441-8.
37. KIBA T, TSUDA H, PALROJKUL C, INOUE S, SUGIMURA T, HIROHASHI S. Mutations of the p53 tumor suppressor gene and the ras gene family in intrahepatic cholangiocellular carcinomas in Japan and Thailand. Mol Carcinog 1993; 8: 312-8.